KRAS G12D
Clinical trials for KRAS G12D explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D trials appear
Sign up with your email to follow new studies for KRAS G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First-in-Human trial launches 'Living Drug' to hunt deadly KRAS cancer mutations
Disease control Recruiting nowThis early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific KRAS gene mutation. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack cancer cells with t…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Experimental t cell therapy targets 'Undruggable' cancer mutation
Disease control Recruiting nowThis early-stage trial is testing a new T cell therapy called RE002 for people with advanced solid tumors that have a specific KRAS G12D mutation. The study will enroll 30 patients to determine safe dosage levels and see if the treatment can shrink tumors. Participants will recei…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug targets multiple KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill targets 'Undruggable' cancer mutations in major trial
Disease control Recruiting nowThis study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …
Matched conditions: KRAS G12D
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for pancreatic cancer patients: experimental immunotherapy offered outside clinical trial
Disease control AVAILABLEThis program provides access to an experimental immunotherapy called ELI-002 7P for patients with a specific type of pancreatic cancer (with KRAS or NRAS mutations) who are at high risk of the cancer coming back after surgery. It is for patients who have no other good treatment o…
Matched conditions: KRAS G12D
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Personalized pills target root cause of painful vascular growths
Disease control Recruiting nowThis trial is testing two different oral medications for people with abnormal, non-cancerous growths of blood or lymph vessels (vascular malformations). The goal is to see if a year of treatment can reduce patients' most bothersome symptoms and shrink the growths. The specific dr…
Matched conditions: KRAS G12D
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC